Den Europæiske Union - dansk - EMA (European Medicines Agency)

n.v. organon - desloratadine, pseudophedrine sulfate - rhinitis, allergisk, sæsonbestemt - nasale præparater - symptomatisk behandling af sæsonbetonet allergisk rhinitis, når den ledsages af næsestop.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - mebeverinhydrochlorid - depotkapsler, hårde - 200 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

viatris aps - mebeverinhydrochlorid - depotkapsler, hårde - 200 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

paranova danmark a/s - mebeverinhydrochlorid - depotkapsler, hårde - 200 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - mebeverinhydrochlorid - depotkapsler, hårde - 200 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - mebeverinhydrochlorid - depotkapsler, hårde - 200 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

aristo pharma gmbh - mebeverinhydrochlorid - kapsler med modificeret udløsning, hårde - 200 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - vcp1338 virus - immunostimulants, antineoplastiske og immunmodulerende midler, immunostimulants, - katte - immunterapi bruges i forbindelse med kirurgi og strålebehandling i katte med fibrosarkom (2-5 cm i diameter) uden metastaser eller lymfeknude involvering, for at reducere risikoen for tilbagefald og øge den tid til tilbagefald (lokalt recidiv eller metastaser).

Den Europæiske Union - dansk - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - hele virion, inaktiveret, der indeholder antigen*: a/vietnam/1194/2004 (h5n1)* produceret i æg - influenza, human; immunization; disease outbreaks - vacciner - prophylax af influenza i en officielt erklæret pandemisk situation. pandemic influenza vaccine bør anvendes i overensstemmelse med officielle retningslinjer.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vacciner - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.